Drugs / Ladarixin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05815173 | Aug 2023 → Aug 2027 expected | respiratory system cancer | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1 | NCT04854642 | Oct → Dec 2020 | — | Dompé Farmaceutici S.p.A | Completed | No outcome recorded |
| Phase 26 trials · 2 missed | ||||||
| Phase 2 | NCT05815186 | Apr 2024 → Apr 2025 | respiratory system cancer | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT05368402 | Sep 2022 → Sep 2023 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05035368 | Sep 2021 → Jun 2023 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04628481 | Jan 2021 → Mar 2025 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Terminated | No outcome recorded |
| Phase 2 | NCT04899271 | Dec 2020 → Apr 2023 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT02814838 | Aug 2016 → May 2019 | type 1 diabetes mellitus | Dompé Farmaceutici S.p.A | Completed | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-01-14 | Dompé Farmaceutici S.p.A | Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D) dompe.com ↗ |
| 2020-06-08 | Dompé Farmaceutici S.p.A | Dompé to Present Phase II Clinical Data for Ladarixin in New-Onset Type 1 Diabetes (T1D) at the American Diabetes Association’s Scientific Sessions dompe.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ladarixin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035368 ↗ |
| Known as | LDX | “AIM: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did...” PMID 37409229 ↗ Jun 2023 |
| Action | Inhibit | “an inhibitor of the CXCR1/2 chemokine receptors” PMID 37409229 ↗ Jun 2023 |
| Route | Oral | “Ladarixin oral capsule” NCT02814838 ↗ |
| Target | CXCR1 | “an inhibitor of the CXCR1/2 chemokine receptors” PMID 37409229 ↗ Jun 2023 |